We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PAREXEL International (PRXL) Q4 Earnings Beat, Up Y/Y
Read MoreHide Full Article
PAREXEL International Corp reported fourth-quarter fiscal 2016 adjusted earnings per share (EPS) of 94 cents, up a significant 19% year over year. The EPS figure also beat the Zacks Consensus Estimate by a couple of cents.
The total revenue reported in the fourth quarter was $628 million which surpassed the year-ago quarter figure of $605 million by 3.7%.
The strong EPS performance was driven by a slight improvement in revenues and the company’s Margin Acceleration Program (MAP) which boosted its margins significantly.
However, the total revenue for fiscal 2016 was $2.43 billion, up 4.2% from fiscal 2015.
Quarter Details
Gross new business wins were $967 million, while net book-to-bill was 1.2.
Total service revenues increased 3% (2.6% on a constant currency basis) to $538.6 million on a year-over-year basis. The upside was driven by higher service and reimbursement revenues.
Clinical Research Services (CRS) service revenues dropped 2.7% to $407.9 million due to decline in revenues from post-approval interventional studies. Moreover, the sequential decline in the CRS gross margin was primarily due to increase in incentive compensation in the quarter.
PAREXEL Consulting (PC) service revenues climbed 59% from the year-ago quarter, driven by strong overall demand and the acquisition of Health Advances, while PAREXEL Informatics (PI) reported a rise of 7.1% led by its regulatory information management and medical imaging solutions, which performed particularly well.
PAREXEL expects first-quarter fiscal 2017 revenues in the range of $520–$530 million. Adjusted earnings are projected in the band of 82–90 cents per share.
For full-year 2017, management anticipates annual savings of approximately $60 million. Going forward, the company’s adjusted operating margin is expected to expand to 120 basis points (bps), with the target range being 14% to 16% for the long term.
For fiscal 2017, management projects revenues in the band of $2.175--$2.205 billion. The adjusted EPS guidance is in the $3.79–$4.05 range.
PAREXEL expects to achieve 10% to 12% growth in revenue, 100 bps to 120 bps expansion in adjusted operating margin and 15% to 20% increase in EPS over the long haul.
Zacks Rank & Key Picks
PAREXEL currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same space include HealthEquity, Inc. (HQY - Free Report) , PRA Health Sciences, Inc. and The Advisory Board Company . While HealthEquity, Inc.and The Advisory Board Company sport a Zacks Rank #1 (Strong Buy), PRA Health Sciences, Inc. carries a Zacks Rank #2. (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PAREXEL International (PRXL) Q4 Earnings Beat, Up Y/Y
PAREXEL International Corp reported fourth-quarter fiscal 2016 adjusted earnings per share (EPS) of 94 cents, up a significant 19% year over year. The EPS figure also beat the Zacks Consensus Estimate by a couple of cents.
The total revenue reported in the fourth quarter was $628 million which surpassed the year-ago quarter figure of $605 million by 3.7%.
The strong EPS performance was driven by a slight improvement in revenues and the company’s Margin Acceleration Program (MAP) which boosted its margins significantly.
However, the total revenue for fiscal 2016 was $2.43 billion, up 4.2% from fiscal 2015.
Quarter Details
Gross new business wins were $967 million, while net book-to-bill was 1.2.
Total service revenues increased 3% (2.6% on a constant currency basis) to $538.6 million on a year-over-year basis. The upside was driven by higher service and reimbursement revenues.
Clinical Research Services (CRS) service revenues dropped 2.7% to $407.9 million due to decline in revenues from post-approval interventional studies. Moreover, the sequential decline in the CRS gross margin was primarily due to increase in incentive compensation in the quarter.
PAREXEL Consulting (PC) service revenues climbed 59% from the year-ago quarter, driven by strong overall demand and the acquisition of Health Advances, while PAREXEL Informatics (PI) reported a rise of 7.1% led by its regulatory information management and medical imaging solutions, which performed particularly well.
PAREXEL INTL CP Price, Consensus and EPS Surprise
PAREXEL INTL CP Price, Consensus and EPS Surprise | PAREXEL INTL CP Quote
Guidance
PAREXEL expects first-quarter fiscal 2017 revenues in the range of $520–$530 million. Adjusted earnings are projected in the band of 82–90 cents per share.
For full-year 2017, management anticipates annual savings of approximately $60 million. Going forward, the company’s adjusted operating margin is expected to expand to 120 basis points (bps), with the target range being 14% to 16% for the long term.
For fiscal 2017, management projects revenues in the band of $2.175--$2.205 billion. The adjusted EPS guidance is in the $3.79–$4.05 range.
PAREXEL expects to achieve 10% to 12% growth in revenue, 100 bps to 120 bps expansion in adjusted operating margin and 15% to 20% increase in EPS over the long haul.
Zacks Rank & Key Picks
PAREXEL currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same space include HealthEquity, Inc. (HQY - Free Report) , PRA Health Sciences, Inc. and The Advisory Board Company . While HealthEquity, Inc.and The Advisory Board Company sport a Zacks Rank #1 (Strong Buy), PRA Health Sciences, Inc. carries a Zacks Rank #2. (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>